Form 4: Supernus Pharmaceuticals CEO Jack Khattar Exercises Options and Sells Shares
SEC Form 4
CEO Jack Khattar exercised stock options and sold shares of Supernus Pharmaceuticals on November 7, 2024.
Summary
- On November 7, 2024, Jack A. Khattar, the President and CEO of Supernus Pharmaceuticals, exercised employee stock options to acquire 125,000 shares of common stock at a price of $9.13 per share.
- Simultaneously, Khattar sold 125,000 shares of Supernus common stock at a weighted average price of $36.68, with individual sales prices ranging from $36.27 to $37.24.
- Following these transactions, Khattar directly owns 926,172 shares of Supernus common stock and indirectly owns 1,022,450 shares through the KBT Trust.
Sentiment
Score: 5
Explanation: This is a neutral disclosure of stock transactions. It doesn't inherently indicate positive or negative sentiment about the company's prospects.
Industry Context
This Form 4 filing is a routine disclosure of insider transactions. It's common for executives to exercise stock options and sell shares for personal financial management.
Key Dates
| Date | Description |
|---|---|
| 03/03/2016 | Option vested in four equal installments beginning on this date. |
| 11/07/2024 | Date of transaction: exercise of stock options and sale of shares. |
| 11/08/2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.